Hospital system Methodist Le Bonheur Healthcare (MLH) disclosed on Tuesday that it is the first hospital system globally to participate in a landmark study using a first-of-its-kind ZETO Instant EEG (electroencephalogram) in the midst of the unprecedented COVID-19 pandemic.
This new FDA-approved product, called zEEG from Zeto Inc, can be set up in less than five minutes and offers a more efficient and comfortable experience for the patient. The patient wears equipment that looks like a high-tech bicycle helmet. The electrodes do not need to be glued to the patient's scalp, do not leave any residue on the patient and there are no wires connected to an amplifier or computer.
Utilising the hospital's ZETO Instant EEG technology, the PPE and exposure time for healthcare workers is reduced significantly.The EEG tests are conducted to detect problems in the brain that may be associated with certain brain disorders including seizures, tumors or strokes. The setup and removal of a typical EEG test takes between 20-30 minutes.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial